Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,201 across all filing types
Latest filing 2025-10-10 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
上海东方华银律师事务所关于灵康药业集团股份有限公司2025年第二次临时股东大会之法律意见书
Regulatory Filings
2025-10-10 Chinese
第五届董事会第一次会议决议公告
Board/Management Information Classification · 100% confidence The document is an announcement of the resolutions passed at the first meeting of the fifth board of directors of Lingkang Pharmaceutical Group Co., Ltd. It details the election of the board chairman, appointment of various board committees, and the hiring of senior management positions such as general manager, financial director, deputy general managers, and securities affairs representative. The content focuses on changes and appointments in the company's board and senior management. There are no financial statements, audit opinions, or other report contents. The document is a formal announcement of board and management changes, fitting the category of Board/Management Information (MANG). The document length is short and it is not a report or presentation but a formal announcement of management changes.
2025-10-10 Chinese
2025年第二次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as the "2025 Second Extraordinary General Meeting (EGM) Meeting Materials" of Lingkang Pharmaceutical Group Co., Ltd. It contains detailed agenda items for the EGM, including proposals on capital changes, cancellation of the supervisory board, amendments to the articles of association, governance system revisions, and election of board members. The document includes meeting procedures, voting instructions, candidate biographies, and legal opinions related to the EGM. There are no financial statements or earnings data, nor is this a transcript or a report publication announcement. The content is clearly materials prepared for and used during a shareholders' meeting, specifically an extraordinary general meeting, which fits the definition of AGM Information (AGM-R) as it is presentation and materials shared during a general meeting (AGM or EGM).
2025-09-26 Chinese
灵康药业集团股份有限公司章程（2025年9月）
Governance Information Classification · 100% confidence The document is titled as the "Company Articles of Association" (公司章程) for Lingkang Pharmaceutical Group Co., Ltd., dated September 2025. It contains detailed chapters on company governance, shareholder rights, board structure, management, financial accounting, profit distribution, auditing, and procedures for shareholder meetings. The content is a comprehensive governance document outlining the internal rules and regulations of the company rather than a financial report or announcement. There is no indication of financial statements, earnings data, voting results, or meeting presentations. The document is not an announcement or a brief summary but a full set of corporate bylaws. Therefore, it fits the category of Governance Information (CGR).
2025-09-22 Chinese
独立董事提名人声明与承诺-王洪信
Regulatory Filings
2025-09-22 Chinese
对外担保决策管理制度（2025年9月修订）
Governance Information Classification · 95% confidence The document is titled '对外担保决策管理制度' which translates to 'External Guarantee Decision Management System' and is issued by Lingkang Pharmaceutical Group Co., Ltd. It is a detailed internal policy document outlining the principles, approval procedures, management, disclosure, and responsibilities related to the company's external guarantees. The content includes governance rules, approval thresholds, disclosure obligations, and internal controls related to guarantees provided by the company. There is no indication that this is a financial report, earnings release, or regulatory filing announcement. It is a governance-related document detailing internal rules and procedures for managing external guarantees. Therefore, the most appropriate classification is Governance Information (CGR). The document length (6487 characters) and detailed procedural content support this classification with high confidence.
2025-09-22 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.